Compare NINE & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NINE | QTTB |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 25.1M |
| IPO Year | 2018 | N/A |
| Metric | NINE | QTTB |
|---|---|---|
| Price | $0.33 | $3.08 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 1.1M | ★ 9.0M |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $571,171,000.00 | N/A |
| Revenue This Year | $4.56 | N/A |
| Revenue Next Year | $1.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.59 | N/A |
| 52 Week Low | $0.29 | $1.35 |
| 52 Week High | $1.78 | $6.37 |
| Indicator | NINE | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 53.80 |
| Support Level | $0.29 | $2.72 |
| Resistance Level | $0.51 | $3.96 |
| Average True Range (ATR) | 0.04 | 0.55 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 19.37 | 9.59 |
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.